Retinoic acid: Topical treatment of senile or actinic keratoses and basal cell carcinomas

1970 ◽  
Vol 1 (4) ◽  
pp. 172-175 ◽  
Author(s):  
W. Bollag ◽  
F. Ott
Keyword(s):  
Retinoic Acid ◽  
Basal Cell ◽  
Topical Treatment ◽  
Actinic Keratoses ◽  
Basal Cell Carcinomas

scholarly journals Imiquimod 5% cream in the treatment of superficial and nodular basal cell carcinomas: study of 10 cases

2002 ◽  
Vol 77 (6) ◽  
pp. 693-698 ◽  
Author(s):  
Cyro Festa Neto
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment ◽  
Imiquimod Cream ◽  
Basal Cell Carcinomas ◽  
Different Types

BACKGROUND: Topical treatment with 5% imiquimod cream has been demonstrated to be effective in patients with basal cell carcinoma. OBJECTIVES: In the present study, efficacy and tolerability of this treatment was analyzed in 10 patients with 13 different types of superficial and nodular basal cell carcinomas. METHODS: Imiquimod cream was applied daily for a mean period of 23 days. RESULTS AND CONCLUSIONS: All patients responded favorably to the drug with healing of the lesions. No recurrence was observed during two to three months of follow up.

Basal Cell Carcinomas and Actinic Keratoses Seen in Dermatological Practice in France: A Cross-Sectional Survey

Dermatology ◽  
2008 ◽  
Vol 216 (3) ◽  
pp. 194-199 ◽  
Author(s):  
P. Bernard ◽  
A. Dupuy ◽  
A. Sasco ◽  
P. Brun ◽  
G. Duru ◽  
...  
Keyword(s):  
Basal Cell ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Actinic Keratoses ◽  
Basal Cell Carcinomas

scholarly journals Expression of retinoic acid receptor proteins in basal cell carcinomas: an immunohistochemical analysis.

1996 ◽  
Vol 44 (12) ◽  
pp. 1415-1420 ◽  
Author(s):  
J Kamradt ◽  
J Reichrath
Keyword(s):  
Retinoic Acid ◽  
Basal Cell ◽  
Retinoic Acid Receptor ◽  
Immunohistochemical Analysis ◽  
Ki 67 ◽  
Weak Staining ◽  
Basal Cell Carcinomas ◽  
Acid Metabolites ◽  
Peripheral Cells ◽  
Labeling Pattern

We analyzed immunohistochemically the expression of RAR proteins in basal cell carcinomas (BCCs; n = 15) in situ. The labeling pattern for the different types of RARs was compared with the staining pattern of the proliferation marker Ki-67 in the same tumors. We found strong immunoreactivity for RAR-alpha and moderate immunoreactivity for RAR-gamma in all BCCs analyzed, whereas no or very weak staining for RAR-beta protein was detected. In contrast to RAR-gamma, which revealed no or only marginal differences in staining intensities, RAR-alpha immunoreactivity was consistently stronger in BCCs compared to adjacent unaffected epidermis. In general, labeling of BCCs for RAR-alpha and RAR-gamma was pronounced in cells of the palisade and peripheral cells, whereas staining in the center of the tumors was heterogeneous. Eleven of the 15 BCCs analyzed revealed no visual correlation in comparing labeling patterns for RAR-alpha and RAR-gamma with the labeling pattern for Ki-67. In four specimens, expression of RAR-alpha, RAR-gamma, and Ki-67 proteins was confined to peripheral tumor cells. Our findings indicate that (a) RAR-alpha and RAR-gamma proteins are, in contrast to RAR-beta, strongly expressed in BCCs; (b) expression of RAR-alpha is upregulated in BCCs compared to keratinocytes of uninvolved epidermis; and (c) BCCs may be targets for potentially preventive or therapeutic treatment with RAR-alpha- or RAR-gamma-selective retinoic acid metabolites.

scholarly journals Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor

2011 ◽  
Vol 131 (8) ◽  
pp. 1735-1744 ◽  
Author(s):  
Hans Skvara ◽  
Frank Kalthoff ◽  
Josef G. Meingassner ◽  
Barbara Wolff-Winiski ◽  
Heinrich Aschauer ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment ◽  
Basal Cell Carcinomas
Sign in / Sign up

Export Citation Format

Share Document